Compare · MMM vs SGP
MMM vs SGP
Side-by-side comparison of 3M Company (MMM) and SpyGlass Pharma Inc. (SGP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and SGP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.20B, about 127.7x SGP ($627.9M).
- SGP has been more active in the news (3 items in the past 4 weeks vs 2 for MMM).
- MMM has more recent analyst coverage (25 ratings vs 5 for SGP).
- Company
- 3M Company
- SpyGlass Pharma Inc.
- Price
- $153.78+0.65%
- $19.07-0.39%
- Market cap
- $80.20B
- $627.9M
- 1M return
- +4.91%
- -
- 1Y return
- +6.64%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 2
- 3
- Recent ratings
- 25
- 5
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Latest MMM
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
- Director Choi Audrey was granted 1,360 shares (SEC Form 4)
- Director Bozeman David P was granted 1,360 shares (SEC Form 4)
Latest SGP
- SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
- SpyGlass Pharma to Participate in Upcoming Investor Conferences
- SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
- SEC Form 10-Q filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- SEC Form 10-K filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
- H.C. Wainwright initiated coverage on SpyGlass Pharma with a new price target